TUESDAY, FEBRUARY 11, 2025 Fourth Quarter & Fiscal Year 2024 Financial Results Business Update and Highlights Financial Results & Guidance Q&A Susan Hubbard EVP, Public Affairs and Investor Relations Michael M. Morrissey, Ph.D. President and CEO Nasdaq: EXEL Today's Agenda Introduction Chris Senner EVP and CFO Amy Peterson, M.D. EVP, Product Development and Medical Affairs and CMO Dana T. Aftab, Ph.D. EVP, Discovery and Translational Research and CSO 2 Forward-Looking Statements This presentation, including ...

Exelixis (EXEL) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.84%. A quarter ago, it was expected that this drug developer would post earnings of $0.42 per share when it actually produced earnings of $0.47, delivering a surprise of 11.90%.Over the last four quarters, the company h ...

Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive pressures and regulatory challenges remain.Exelixis (EXEL -2.06%), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise in both revenue and earnings. Announced on Feb. 11, 2025, the earnings release showcased Exelixis's performance amidst a challenging oncology landscape, with revenues surpassing year ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 3, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30235 EXELIXIS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or De ...

Exhibit 99.1 Investor Contacts: Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 shubbard@exelixis.com Media Contact: Hal Mackins For Exelixis, Inc. 415-994-0040 hal@torchcommunications.com Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 – Cabozantinib franchise achieves approximately $1 ...

Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, investors can acquire shares of companies whose long-term prospects look exciting, and all for the price of a few breakfast items. As long as investors hold on to these companies' shares for a while and add to their positions regularly, strong returns await them.That said, let's discuss two stocks, each of which is trading for less than $40, that are worth investors' serious consideratio ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Techne (TECH) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets compa ...

Core Insights - Exelixis (EXEL) is expected to report quarterly earnings of $0.51 per share, reflecting a 54.6% increase year-over-year, with revenues forecasted at $562.88 million, a 17.4% increase from the previous year [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate for the quarter has been revised upward by 3.3%, indicating analysts' reassessment of their initial forecasts [2]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenues- Net product' to be $505.98 million, representing a 17.9% increase from the prior-year quarter [5]. - 'Revenues- Net product- CABOMETYX' is projected to reach $501.25 million, indicating a 17.2% year-over-year change [5]. - 'Revenues- License' is expected to be $54.80 million, reflecting a 21.2% increase from the previous year [5]. - 'Revenues- Collaboration services' is forecasted at $1.94 million, which indicates a significant decline of 61.9% from the year-ago quarter [6]. Stock Performance - Exelixis shares have decreased by 2.8% over the past month, contrasting with the Zacks S&P 500 composite's increase of 2.1% [6]. - With a Zacks Rank 2 (Buy), Exelixis is anticipated to outperform the overall market in the near term [6].

Shares of Exelixis (EXEL) were down 5.13% on Jan. 24, following a downgrade in rating by analysts at Oppenheimer.Oppenheimer downgraded EXEL to “Perform” from “Outperform” as the analysts were concerned about the potential differentiation of pipeline candidate zanzalintinib versus cabozantinib following the abstract for STELLAR-001 study at American Society of Clinical Oncology 2025 Gastrointestinal Cancers Symposium (ASCO GI).While Oppenheimer believes data from STELLAR-001 likely derisk the late-stage STE ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...